期刊文献+

塞来考昔对女性卵巢功能的影响 被引量:1

Influence of celecoxib on ovary function
下载PDF
导出
摘要 目的 :观察塞来考昔 (celecoxib)对女性卵巢功能的影响。方法 :5 6例痛经病人分为 2组 ,A组给予塞来考昔治疗 1wk ,B组给予山莨菪碱治疗1wk ,采用对照的方法进行临床试验。结果 :塞来考昔对治疗前后病人性激素 (PRL ,E2 ,LH ,FSH)水平无明显影响 (P >0 .0 5 ) ,与山莨菪碱治疗组比较无显著差异 (P >0 .0 5 ) ,其对滤泡直径的影响与山莨菪碱治疗组比较亦无显著差异 [(2 0 .1±s 1.3)mmvs(19.4± 1.1)mm ,P >0 .0 5 ]。结论 :短期使用塞来考昔对女性卵巢功能可能无明显影响。 AIM: To investigate the influence of celecoxib therapy on ovary function. METHODS: Fifty-six women with menstrual pain were divided into two groups (group A and group B),with group A treated with celecoxib and group B with anisodamine for 1 wk,sex hormone concentrations and the diameter of ovary follicle were compared. RESULTS: Sex hormone concentrations (PRL,E_2,LH and FSH)do not be affected before and after treatment with celecoxib ( P >0.05)and have no significant difference compared with anisodamine treating. The diameter of ovary follicle in group A do not be changed compared with group B( P >0.05). CONCLUSION: Short-term using of celecoxib do not affects ovary function.
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2004年第8期538-539,共2页 Chinese Journal of New Drugs and Clinical Remedies
关键词 卵巢功能试验 消炎药 非甾类 药物疗法 塞来考昔 ovarian function tests anti-inflammatory agents,non-steroidal drug therapy celecoxib
  • 相关文献

参考文献1

二级参考文献2

共引文献2

同被引文献16

  • 1Zhao SZ, Mcmillen JI, Markenson JA, et al. Evaluation of the functional status aspects of Health-Related Quality of Life of patients with osteoarthritis treated with Celecoxib. Pharmacotherapy, 1999, 19(11): 1269-1278.
  • 2Zhao SZ, FiechtnerJJ, Tindall EA, et al. Evaluation of Health- Related Quality of Life of rheumatoid arthritis patients treated with Celecoxib. Arthritis Care and Research, 2000, 13(2): 112-121.
  • 3Becker MC, Wang TH, Wisniewski L, et al. Rationale, design, and governance of prospective randomized evaluation of Celecoxib inte- grated safety versus Ibuprofen or Naproxen (PRECISION), a cardio- vascular end point trial of nonsteroidal anti-inflammatory agents in patients with arthritis. Am Heart J, 2009, 157(4): 606-612.
  • 4Solomon SD, Wittes J, Finn PV, et al. Cardiovascular risk of Celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulatio, 2008, 117(16): 2104-2113.
  • 5Lelorier J, Fitzsimon C, Keresteci M, et al. Drug utilization review of Celecoxib in Ontario. Rheumatology, 2003, 42(suppl 3): 11-16.
  • 6Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics, 2004, 22(2 Suppl 1): 1-12.
  • 7Nivsrkar M. Improvement in circulating superoxide dismutase levels: Role of nonsteroidal anti-inflammatory drugs in rheumatoid arthritis biochemical and biophysical. Research Communications, 2000, 270(3): 714-716.
  • 8Niederberger E, Manderscheid C, Gr6sch S, et al. Effects of the se- lective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. Biochem Pharmacol, 2004, 68(2): 341-350.
  • 9Laine L, Connor LG, Reicin A, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or Coxib Use. Gastroenterology, 2003, 124(2): 288-292.
  • 10Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 1996, 17(1): 1-12.

引证文献1

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部